[Examining the effect of amiodarone on the lung: prospective follow-up data].
Amiodarone (A) that belongs to Class III antiarrhythmics is a highly antiarrhythmic agents not only in treating, but in preventing various cardiac arrhythmias. However, its prolonged treatment may have an adverse life-threatening effect on the lung in 1-10% of patients. The purpose of our study was to verify the safe effect of A on the lung. Forty-one patients receiving A were examined in the period of its saturation and for the following 6 months. A hundred and forty-nine patients treated with its maintaining doses long (for 11 years) were also studied. Lung X-ray films and spirograms were repeated every 1-3 months at the beginning of therapy and then every 6 months. Side pulmonary effects were not observed. The findings may lead to the conclusion that comparatively small maintaining doses of A are safe for the patient.
Intensive Care Medicine Clinic, Kaunas University of Medicine, Ministry of Health of the Russian Federation.
D I
DI
Reĭngardene
A P
AP
Azaravichene
I Z
IZ
Korobkova
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000638:Amiodarone / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000517:prevention & control; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011859:Radiography; D013147:Spirometry; D013997:Time Factors
D000889:Anti-Arrhythmia Agents; D000638:Amiodarone